{"id":51916,"date":"2024-07-24T19:29:35","date_gmt":"2024-07-24T18:29:35","guid":{"rendered":"https:\/\/www.innovationnewsnetwork.com\/?p=51916"},"modified":"2024-10-15T19:40:27","modified_gmt":"2024-10-15T18:40:27","slug":"defence-therapeutics-advances-radio-immuno-conjugates-cnri-h-program-approval","status":"publish","type":"post","link":"https:\/\/www.innovationnewsnetwork.com\/defence-therapeutics-advances-radio-immuno-conjugates-cnri-h-program-approval\/51916\/","title":{"rendered":"Defence Therapeutics advances radio-immuno-conjugates with CNRI-H Program approval"},"content":{"rendered":"<h2><a href=\"https:\/\/defencetherapeutics.com\/\" target=\"_blank\" rel=\"noopener\">Defence Therapeutics Inc.<\/a>\u00a0has announced a significant milestone in its radio-immuno-conjugates project.<\/h2>\n<p>The\u00a0<a href=\"https:\/\/www.cnl.ca\/health-science-2\/canadian-nuclear-research-initiative-health-cnri-h\/\" target=\"_blank\" rel=\"noopener\">Canadian Nuclear Research Initiative Health (CNRI-H) Program<\/a>\u00a0application by Defence Therapeutics has been approved by the Canadian Nuclear Laboratories (CNL), facilitating the acceleration of their innovative research.<\/p>\n<h3>Focus of the CNRI-H project<\/h3>\n<p>The CNRI-H project by Defence Therapeutics will concentrate on the synthesis and evaluation of novel constructs, specifically variations of\u00a0<sup>111<\/sup>In-AccuTOX\u00ae-Trastuzumab.<\/p>\n<p>The primary aim is to establish that the AccuTOX\u00ae moiety is a crucial enhancement to conventional\u00a0<sup>111<\/sup>In-Trastuzumab constructs.<\/p>\n<p>This modification is designed to avoid endosome entrapment and ensure nuclear localisation, where\u00a0<sup>111<\/sup>In will emit Auger Electrons (AEs) to\u00a0<a href=\"https:\/\/www.healtheuropa.com\/defences-arm-x-vaccine-completely-inhibits-ovarian-cancer-growth-in-treated-animals\/123684\/\">destroy cancer cells<\/a>. Additionally, AccuTOX\u00ae will unleash its immune-boosting properties, creating a synergistic effect.<\/p>\n<h3>Development and testing<\/h3>\n<p>Selected AccuTOX\u00ae constructs will be assessed based on their stability, solubility, and biochemical properties.<\/p>\n<p>These constructs will be conjugated to the trastuzumab antibody, radiolabeled with\u00a0<sup>111<\/sup>In, and characterised both in vitro and in vivo to determine their effectiveness in targeting and killing cancer cells.<\/p>\n<p>The ultimate goal is to identify a biologically active\u00a0<sup>111<\/sup>In-AccuTOX\u00ae-Trastuzumab molecule that demonstrates higher potency against solid tumours resistant to current HER2-targeting therapies, such as therapeutic antibodies (e.g., trastuzumab) and antibody-drug conjugates (e.g., Kadcyla\u00ae).<\/p>\n<p>The collaborative project aims to:<\/p>\n<ul>\n<li>Synthesise and Characterise: Develop AccuTOX\u00ae-Trastuzumab antibody conjugates, radiolabel them with\u00a0<sup>111<\/sup>In, and conduct structural and cellular analyses. This includes identifying drug-antibody ratios, specific activity, stability, and cytotoxic effects in vitro.<\/li>\n<li>In Vivo Studies: Perform animal studies in rodents to evaluate biodistribution, pharmacokinetic profiles, and therapeutic potency of selected\u00a0<sup>111<\/sup>In-AccuTOX\u00ae-Trastuzumab constructs.<\/li>\n<\/ul>\n<p>Sebastien Plouffe, CEO of Defence Therapeutics, commented: \u201cWe are proud to have this opportunity to collaborate with the Canadian Nuclear Laboratories and to advance Defence\u2019s radio-immuno-conjugates program for the benefit of the cancer\u2019s patients.<\/p>\n<p>\u201cThe CNL scientific team dedicated to our project is very strong and will definitely accelerate and reinforce Defence\u2019s strength in this renowned and fast-growing radiopharmaceuticals field.\u201d<\/p>\n<h3>About the CNRI-H Program<\/h3>\n<p>The CNRI-H program by CNL is designed to contribute to the health of Canadians by providing financial support and expertise to the healthcare community.<\/p>\n<p>This program aims to advance new life-saving radiopharmaceutical solutions by integrating funding and project execution.<\/p>\n<p>The ultimate goal is to optimise the production of therapeutic isotopes and facilitate the clinical translation of targeted radiopharmaceuticals, thereby enhancing the safety and efficacy of therapies involving radiopharmaceuticals for the benefit of Canadians.<\/p>\n<p>In summary, the CNRI-H program approval marks a pivotal step for Defence Therapeutics, enabling them to accelerate their radio-immuno-conjugates project and potentially offer new,\u00a0<a href=\"https:\/\/defencetherapeutics.com\/cancer-therapeutics\/\" target=\"_blank\" rel=\"noopener\">potent treatments for cancer patients<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Defence Therapeutics Inc.\u00a0has announced a significant milestone in its radio-immuno-conjugates project. The\u00a0Canadian Nuclear Research Initiative Health (CNRI-H) Program\u00a0application by Defence Therapeutics has been approved by the Canadian Nuclear Laboratories (CNL), facilitating the acceleration of their innovative research. Focus of the CNRI-H project The CNRI-H project by Defence Therapeutics will concentrate on the synthesis and evaluation [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":51912,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[23535],"tags":[24628],"acf":[],"yoast_head":"\n<title>Defence Therapeutics advances radio-immuno-conjugates with CNRI-H Program approval | Innovation News Network<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.innovationnewsnetwork.com\/defence-therapeutics-advances-radio-immuno-conjugates-cnri-h-program-approval\/51916\/\" \/>\n<meta property=\"og:locale\" content=\"en_GB\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Defence Therapeutics advances radio-immuno-conjugates with CNRI-H Program approval\" \/>\n<meta property=\"og:description\" content=\"Defence Therapeutics Inc.\u00a0has announced a significant milestone in its radio-immuno-conjugates project. The\u00a0Canadian Nuclear Research Initiative Health (CNRI-H) Program\u00a0application by Defence Therapeutics has been approved by the Canadian Nuclear Laboratories (CNL), facilitating the acceleration of their innovative research. Focus of the CNRI-H project The CNRI-H project by Defence Therapeutics will concentrate on the synthesis and evaluation [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.innovationnewsnetwork.com\/defence-therapeutics-advances-radio-immuno-conjugates-cnri-h-program-approval\/51916\/\" \/>\n<meta property=\"og:site_name\" content=\"Innovation News Network\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/InnoNewsNetwork\" \/>\n<meta property=\"article:published_time\" content=\"2024-07-24T18:29:35+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-10-15T18:40:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.innovationnewsnetwork.com\/wp-content\/uploads\/2024\/10\/inn-feature-image-defence-therapeutics-003.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1920\" \/>\n\t<meta property=\"og:image:height\" content=\"1080\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Innovation News Network\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@InnoNewsNetwork\" \/>\n<meta name=\"twitter:site\" content=\"@InnoNewsNetwork\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Innovation News Network\" \/>\n\t<meta name=\"twitter:label2\" content=\"Estimated reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.innovationnewsnetwork.com\/defence-therapeutics-advances-radio-immuno-conjugates-cnri-h-program-approval\/51916\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.innovationnewsnetwork.com\/defence-therapeutics-advances-radio-immuno-conjugates-cnri-h-program-approval\/51916\/\"},\"author\":{\"name\":\"Innovation News Network\",\"@id\":\"https:\/\/www.innovationnewsnetwork.com\/#\/schema\/person\/38f0969540c25d7fff4c7accd510863e\"},\"headline\":\"Defence Therapeutics advances radio-immuno-conjugates with CNRI-H Program approval\",\"datePublished\":\"2024-07-24T18:29:35+00:00\",\"dateModified\":\"2024-10-15T18:40:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.innovationnewsnetwork.com\/defence-therapeutics-advances-radio-immuno-conjugates-cnri-h-program-approval\/51916\/\"},\"wordCount\":437,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/www.innovationnewsnetwork.com\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.innovationnewsnetwork.com\/defence-therapeutics-advances-radio-immuno-conjugates-cnri-h-program-approval\/51916\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.innovationnewsnetwork.com\/wp-content\/uploads\/2024\/10\/inn-feature-image-defence-therapeutics-003.jpg\",\"keywords\":[\"PP Defence Therapeutics\"],\"articleSection\":[\"Partner News\"],\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/www.innovationnewsnetwork.com\/defence-therapeutics-advances-radio-immuno-conjugates-cnri-h-program-approval\/51916\/#respond\"]}],\"copyrightYear\":\"2024\",\"copyrightHolder\":{\"@id\":\"https:\/\/www.innovationnewsnetwork.com\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.innovationnewsnetwork.com\/defence-therapeutics-advances-radio-immuno-conjugates-cnri-h-program-approval\/51916\/\",\"url\":\"https:\/\/www.innovationnewsnetwork.com\/defence-therapeutics-advances-radio-immuno-conjugates-cnri-h-program-approval\/51916\/\",\"name\":\"Defence Therapeutics advances radio-immuno-conjugates with CNRI-H Program approval | Innovation News Network\",\"isPartOf\":{\"@id\":\"https:\/\/www.innovationnewsnetwork.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.innovationnewsnetwork.com\/defence-therapeutics-advances-radio-immuno-conjugates-cnri-h-program-approval\/51916\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.innovationnewsnetwork.com\/defence-therapeutics-advances-radio-immuno-conjugates-cnri-h-program-approval\/51916\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.innovationnewsnetwork.com\/wp-content\/uploads\/2024\/10\/inn-feature-image-defence-therapeutics-003.jpg\",\"datePublished\":\"2024-07-24T18:29:35+00:00\",\"dateModified\":\"2024-10-15T18:40:27+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.innovationnewsnetwork.com\/defence-therapeutics-advances-radio-immuno-conjugates-cnri-h-program-approval\/51916\/#breadcrumb\"},\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.innovationnewsnetwork.com\/defence-therapeutics-advances-radio-immuno-conjugates-cnri-h-program-approval\/51916\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\/\/www.innovationnewsnetwork.com\/defence-therapeutics-advances-radio-immuno-conjugates-cnri-h-program-approval\/51916\/#primaryimage\",\"url\":\"https:\/\/www.innovationnewsnetwork.com\/wp-content\/uploads\/2024\/10\/inn-feature-image-defence-therapeutics-003.jpg\",\"contentUrl\":\"https:\/\/www.innovationnewsnetwork.com\/wp-content\/uploads\/2024\/10\/inn-feature-image-defence-therapeutics-003.jpg\",\"width\":1920,\"height\":1080,\"caption\":\"Defence Therapeutics advances radio-immuno-conjugates with CNRI-H Program approval\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.innovationnewsnetwork.com\/defence-therapeutics-advances-radio-immuno-conjugates-cnri-h-program-approval\/51916\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.innovationnewsnetwork.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Defence Therapeutics advances radio-immuno-conjugates with CNRI-H Program approval\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.innovationnewsnetwork.com\/#website\",\"url\":\"https:\/\/www.innovationnewsnetwork.com\/\",\"name\":\"Innovation News Network\",\"description\":\"Science, Research &amp; Innovation News\",\"publisher\":{\"@id\":\"https:\/\/www.innovationnewsnetwork.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.innovationnewsnetwork.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-GB\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.innovationnewsnetwork.com\/#organization\",\"name\":\"Innovation News Network\",\"url\":\"https:\/\/www.innovationnewsnetwork.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\/\/www.innovationnewsnetwork.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.innovationnewsnetwork.com\/wp-content\/uploads\/2022\/01\/inn-logo-yoast-seo-organisation-1920-1080-001.jpg\",\"contentUrl\":\"https:\/\/www.innovationnewsnetwork.com\/wp-content\/uploads\/2022\/01\/inn-logo-yoast-seo-organisation-1920-1080-001.jpg\",\"width\":1920,\"height\":1080,\"caption\":\"Innovation News Network\"},\"image\":{\"@id\":\"https:\/\/www.innovationnewsnetwork.com\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/InnoNewsNetwork\",\"https:\/\/x.com\/InnoNewsNetwork\",\"https:\/\/www.linkedin.com\/company\/innovation-news-network\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.innovationnewsnetwork.com\/#\/schema\/person\/38f0969540c25d7fff4c7accd510863e\",\"name\":\"Innovation News Network\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\/\/www.innovationnewsnetwork.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/deb82a7db772be9bb29280b33f0291e9?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/deb82a7db772be9bb29280b33f0291e9?s=96&d=mm&r=g\",\"caption\":\"Innovation News Network\"},\"url\":\"https:\/\/www.innovationnewsnetwork.com\/author\/mattkilgariff\/\"}]}<\/script>\n","yoast_head_json":{"title":"Defence Therapeutics advances radio-immuno-conjugates with CNRI-H Program approval | Innovation News Network","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.innovationnewsnetwork.com\/defence-therapeutics-advances-radio-immuno-conjugates-cnri-h-program-approval\/51916\/","og_locale":"en_GB","og_type":"article","og_title":"Defence Therapeutics advances radio-immuno-conjugates with CNRI-H Program approval","og_description":"Defence Therapeutics Inc.\u00a0has announced a significant milestone in its radio-immuno-conjugates project. The\u00a0Canadian Nuclear Research Initiative Health (CNRI-H) Program\u00a0application by Defence Therapeutics has been approved by the Canadian Nuclear Laboratories (CNL), facilitating the acceleration of their innovative research. Focus of the CNRI-H project The CNRI-H project by Defence Therapeutics will concentrate on the synthesis and evaluation [&hellip;]","og_url":"https:\/\/www.innovationnewsnetwork.com\/defence-therapeutics-advances-radio-immuno-conjugates-cnri-h-program-approval\/51916\/","og_site_name":"Innovation News Network","article_publisher":"https:\/\/www.facebook.com\/InnoNewsNetwork","article_published_time":"2024-07-24T18:29:35+00:00","article_modified_time":"2024-10-15T18:40:27+00:00","og_image":[{"width":1920,"height":1080,"url":"https:\/\/www.innovationnewsnetwork.com\/wp-content\/uploads\/2024\/10\/inn-feature-image-defence-therapeutics-003.jpg","type":"image\/jpeg"}],"author":"Innovation News Network","twitter_card":"summary_large_image","twitter_creator":"@InnoNewsNetwork","twitter_site":"@InnoNewsNetwork","twitter_misc":{"Written by":"Innovation News Network","Estimated reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.innovationnewsnetwork.com\/defence-therapeutics-advances-radio-immuno-conjugates-cnri-h-program-approval\/51916\/#article","isPartOf":{"@id":"https:\/\/www.innovationnewsnetwork.com\/defence-therapeutics-advances-radio-immuno-conjugates-cnri-h-program-approval\/51916\/"},"author":{"name":"Innovation News Network","@id":"https:\/\/www.innovationnewsnetwork.com\/#\/schema\/person\/38f0969540c25d7fff4c7accd510863e"},"headline":"Defence Therapeutics advances radio-immuno-conjugates with CNRI-H Program approval","datePublished":"2024-07-24T18:29:35+00:00","dateModified":"2024-10-15T18:40:27+00:00","mainEntityOfPage":{"@id":"https:\/\/www.innovationnewsnetwork.com\/defence-therapeutics-advances-radio-immuno-conjugates-cnri-h-program-approval\/51916\/"},"wordCount":437,"commentCount":0,"publisher":{"@id":"https:\/\/www.innovationnewsnetwork.com\/#organization"},"image":{"@id":"https:\/\/www.innovationnewsnetwork.com\/defence-therapeutics-advances-radio-immuno-conjugates-cnri-h-program-approval\/51916\/#primaryimage"},"thumbnailUrl":"https:\/\/www.innovationnewsnetwork.com\/wp-content\/uploads\/2024\/10\/inn-feature-image-defence-therapeutics-003.jpg","keywords":["PP Defence Therapeutics"],"articleSection":["Partner News"],"inLanguage":"en-GB","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.innovationnewsnetwork.com\/defence-therapeutics-advances-radio-immuno-conjugates-cnri-h-program-approval\/51916\/#respond"]}],"copyrightYear":"2024","copyrightHolder":{"@id":"https:\/\/www.innovationnewsnetwork.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/www.innovationnewsnetwork.com\/defence-therapeutics-advances-radio-immuno-conjugates-cnri-h-program-approval\/51916\/","url":"https:\/\/www.innovationnewsnetwork.com\/defence-therapeutics-advances-radio-immuno-conjugates-cnri-h-program-approval\/51916\/","name":"Defence Therapeutics advances radio-immuno-conjugates with CNRI-H Program approval | Innovation News Network","isPartOf":{"@id":"https:\/\/www.innovationnewsnetwork.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.innovationnewsnetwork.com\/defence-therapeutics-advances-radio-immuno-conjugates-cnri-h-program-approval\/51916\/#primaryimage"},"image":{"@id":"https:\/\/www.innovationnewsnetwork.com\/defence-therapeutics-advances-radio-immuno-conjugates-cnri-h-program-approval\/51916\/#primaryimage"},"thumbnailUrl":"https:\/\/www.innovationnewsnetwork.com\/wp-content\/uploads\/2024\/10\/inn-feature-image-defence-therapeutics-003.jpg","datePublished":"2024-07-24T18:29:35+00:00","dateModified":"2024-10-15T18:40:27+00:00","breadcrumb":{"@id":"https:\/\/www.innovationnewsnetwork.com\/defence-therapeutics-advances-radio-immuno-conjugates-cnri-h-program-approval\/51916\/#breadcrumb"},"inLanguage":"en-GB","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.innovationnewsnetwork.com\/defence-therapeutics-advances-radio-immuno-conjugates-cnri-h-program-approval\/51916\/"]}]},{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/www.innovationnewsnetwork.com\/defence-therapeutics-advances-radio-immuno-conjugates-cnri-h-program-approval\/51916\/#primaryimage","url":"https:\/\/www.innovationnewsnetwork.com\/wp-content\/uploads\/2024\/10\/inn-feature-image-defence-therapeutics-003.jpg","contentUrl":"https:\/\/www.innovationnewsnetwork.com\/wp-content\/uploads\/2024\/10\/inn-feature-image-defence-therapeutics-003.jpg","width":1920,"height":1080,"caption":"Defence Therapeutics advances radio-immuno-conjugates with CNRI-H Program approval"},{"@type":"BreadcrumbList","@id":"https:\/\/www.innovationnewsnetwork.com\/defence-therapeutics-advances-radio-immuno-conjugates-cnri-h-program-approval\/51916\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.innovationnewsnetwork.com\/"},{"@type":"ListItem","position":2,"name":"Defence Therapeutics advances radio-immuno-conjugates with CNRI-H Program approval"}]},{"@type":"WebSite","@id":"https:\/\/www.innovationnewsnetwork.com\/#website","url":"https:\/\/www.innovationnewsnetwork.com\/","name":"Innovation News Network","description":"Science, Research &amp; Innovation News","publisher":{"@id":"https:\/\/www.innovationnewsnetwork.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.innovationnewsnetwork.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-GB"},{"@type":"Organization","@id":"https:\/\/www.innovationnewsnetwork.com\/#organization","name":"Innovation News Network","url":"https:\/\/www.innovationnewsnetwork.com\/","logo":{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/www.innovationnewsnetwork.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.innovationnewsnetwork.com\/wp-content\/uploads\/2022\/01\/inn-logo-yoast-seo-organisation-1920-1080-001.jpg","contentUrl":"https:\/\/www.innovationnewsnetwork.com\/wp-content\/uploads\/2022\/01\/inn-logo-yoast-seo-organisation-1920-1080-001.jpg","width":1920,"height":1080,"caption":"Innovation News Network"},"image":{"@id":"https:\/\/www.innovationnewsnetwork.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/InnoNewsNetwork","https:\/\/x.com\/InnoNewsNetwork","https:\/\/www.linkedin.com\/company\/innovation-news-network\/"]},{"@type":"Person","@id":"https:\/\/www.innovationnewsnetwork.com\/#\/schema\/person\/38f0969540c25d7fff4c7accd510863e","name":"Innovation News Network","image":{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/www.innovationnewsnetwork.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/deb82a7db772be9bb29280b33f0291e9?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/deb82a7db772be9bb29280b33f0291e9?s=96&d=mm&r=g","caption":"Innovation News Network"},"url":"https:\/\/www.innovationnewsnetwork.com\/author\/mattkilgariff\/"}]}},"publishpress_future_action":{"enabled":false,"date":"2025-03-06 06:13:50","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category"},"_links":{"self":[{"href":"https:\/\/www.innovationnewsnetwork.com\/wp-json\/wp\/v2\/posts\/51916"}],"collection":[{"href":"https:\/\/www.innovationnewsnetwork.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.innovationnewsnetwork.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.innovationnewsnetwork.com\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.innovationnewsnetwork.com\/wp-json\/wp\/v2\/comments?post=51916"}],"version-history":[{"count":3,"href":"https:\/\/www.innovationnewsnetwork.com\/wp-json\/wp\/v2\/posts\/51916\/revisions"}],"predecessor-version":[{"id":51924,"href":"https:\/\/www.innovationnewsnetwork.com\/wp-json\/wp\/v2\/posts\/51916\/revisions\/51924"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.innovationnewsnetwork.com\/wp-json\/wp\/v2\/media\/51912"}],"wp:attachment":[{"href":"https:\/\/www.innovationnewsnetwork.com\/wp-json\/wp\/v2\/media?parent=51916"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.innovationnewsnetwork.com\/wp-json\/wp\/v2\/categories?post=51916"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.innovationnewsnetwork.com\/wp-json\/wp\/v2\/tags?post=51916"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}